HRMY Q4 2024 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$201M+19.5% YoY

Gross Profit

$147M73.0% margin

Operating Income

$56M27.7% margin

Net Income

$49M24.6% margin

EPS (Diluted)

$0.85

QoQ Revenue Growth

+8.2%

Cash Flow

Operating Cash Flow

$76M

Free Cash Flow

$75M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$999M

Total Liabilities

$340M

Stockholders' Equity

$659M

Cash & Equivalents

$453M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$201M	$168M	+19.5%
Gross Profit	$147M	$125M	+17.2%
Operating Income	$56M	$40M	+38.6%
Net Income	$49M	$27M	+85.9%